organotherapeutics
OrganoTherapeutics develops patient-specific brain organoid models and provides research services for preclinical therapeutic testing against brain disorders.
Free verification proves website control and lets the business keep this profile accurate.
OverviewAbout organotherapeutics
The company develops patient-specific cell culture models, including midbrain, cerebral, and striatum organoids and assembloids, to study therapeutic effects on the human brain. It offers tailored research projects that include experimental work, data analysis, and interpretation, with data optionally integrated into a Parkinson’s Disease Knowledge Graph.
ProductsWhat organotherapeutics builds
Patient-Specific Brain Organoids
Midbrain, cerebral, and striatum organoids, along with assembloids, are developed to replicate Parkinson's pathology for preclinical testing.
Preclinical Research Services
Tailored projects cover experimental execution, data analysis, and reporting for therapeutic development against brain disorders.
Track recordMilestones & press
press
Reached profitability and continued funding operations through clients and grants
product
Featured in The Elevator - Silicon Luxembourg reported that OrganoTherapeutics was featured in episode 37 of The Elevator with Dr. Isabel Rosety.
grant
Completed accelerator programs and received major European research grants
press
Funding from KHAN-I - OrganoTherapeutics announced that KHAN-I obtained shares in the company.
product
Announced as a spin-off offering midbrain organoids for Parkinson’s research
Knowledge baseQuestions people ask
What does organotherapeutics do?
organotherapeutics: OrganoTherapeutics develops patient-specific brain organoid models and provides research services for preclinical therapeutic testing against brain disorders.
Where is organotherapeutics based?
organotherapeutics is based in Esch-sur-Alzette, Luxembourg.
Who are the founders and key executives of organotherapeutics?
Jens Schwamborn serves as Chief Executive Officer and co-founder. Javier Jarazo acts as Chief Scientific Officer and co-founder. Silvia Bolognin is also listed as a co-founder.
What investment has organotherapeutics secured?
In August 2023, the company received seed funding from KHAN-I. As part of this arrangement, KHAN-I obtained shares in the business.
Has organotherapeutics participated in any industry interviews or podcasts?
In May 2024, the company was featured in episode 37 of The Elevator. The interview was conducted by Dr Isabel Rosety and reported by Silicon Luxembourg.
ProvenanceEvery field, with its source
Open a source to inspect the evidence. Labels distinguish official records, company-published facts, third-party reporting, and derived values.
| Field | Value | Source | Checked |
|---|---|---|---|
| displayName | organotherapeutics | organo-therapeutics.comcompanyOwned ↗ | |
| sector | Biotechnology / Neuroscience Research / Therapeutic Development | organo-therapeutics.comcompanyOwned ↗ | |
| legalName | OrganoTherapeutics GmbH | Luxembourg Business Registers (RCS)official ↗ | |
| rcsNumber | B237755 | Luxembourg Business Registers (RCS)official ↗ | |
| legalForm | SARL | Luxembourg Business Registers (RCS)official ↗ | |
| registrationDate | 2019-09-24 | Luxembourg Business Registers (RCS)official ↗ | |
| registeredOffice | 29, Rue Henri Koch, L-4354 Esch-sur-Alzette | Luxembourg Business Registers (RCS)official ↗ | |
| operationalAddress (company-stated) | 29 Rue Henri Koch, 4354 Esch-sur-Alzette | organo-therapeutics.comcompanyOwned ↗ | |
| founded | 2019 | Luxembourg Business Registers (RCS)official ↗ | |
| teamSize | 1-10 employees | researcher note (source pending)pending | · |
| stage | seed (No disclosed institutional equity round on record) | derived from funding records and team size on filethirdParty | |
| coordinates | 49.509315443, 5.965989325 (29, Rue Henri Koch, L-4354 Esch-sur-Alzette) | Geoportail BD-Adressesofficial ↗ | |
| contactEmail | jens.schwamborn@organo-therapeutics.com | organo-therapeutics.comcompanyOwned ↗ | |
| contactPhone | +352 27 69 48 45 | pharmchoices.comthirdParty ↗ | |
| https://www.linkedin.com/company/organotherapeutics | linkedin.comthirdParty ↗ | ||
| longDescription | (about text) | organo-therapeutics.comcompanyOwned ↗ | |
| annualAccounts | pending | Centrale des Bilans queuedpending | · |
| publicPresence | LinkedIn + 9 press/news sources | linkedin.comthirdParty ↗ | |
| logo | /logos/organotherapeutics.png | images.squarespace-cdn.comthirdParty ↗ |